MEXICO
CITY, Oct. 2, 2024 /PRNewswire/ -- Genomma
Lab Internacional, S.A.B. de C.V. (BMV:
LABB) ("Genomma Lab" or "the Company"), one of the leading
pharmaceutical and personal care product companies in Mexico with an expanding international
presence, today announced that it has received Good Manufacturing
Practices ("GMP") certification from the Mexican Ministry of
Health's Federal Committee for Protection from Sanitary Risks for
its oral liquid, topical liquid and tablet coating manufacturing
production at Genomma Lab's Medicinas y Medicamentos Nacionales,
S.A. de C.V. manufacturing facility in the State of Mexico.
About Genomma Lab Internacional
Genomma
Lab Internacional, S.A.B. de
C.V. is one of the fastest growing pharmaceutical and
personal care products companies in Latin
America. Genomma Lab develops, sells and
markets a broad range of Premium branded products, many of which
are leaders in the categories in which they compete in terms of
sales and market share. The Company has a sound business model
through a unique combination of a new product development process,
consumer oriented marketing, a broad retail distribution network
and a low‐cost, highly flexible supply chain operating model. For
more information visit: www.genommalab.com
Genomma Lab's shares are listed on the Mexican Stock Exchange
under the ticker "LABB" (Bloomberg:
LABB:MM).
Note on Forward-Looking Statements
This report may
contain certain forward-looking statements and information relating
to the Company that reflect the current views and/or expectations
of the Company and its management with respect to its performance,
business and future events. Forward looking statements include,
without limitation, any statement that may predict, forecast,
indicate or imply future results, performance or achievements, and
may contain words like "believe," "anticipate," "expect,"
"envisages," "will likely result," or any other words or phrases of
similar meaning. Such statements are subject to a number of risks,
uncertainties and assumptions. We caution you that a number of
important factors could cause actual results to differ materially
from the plans, objectives, expectations, estimates and intentions
expressed in this presentation and in oral statements made by
authorized officers of the Company. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of their dates. Risks and uncertainties include, but
are not limited to: risks related to the impact of the COVID-19
global pandemic, such as the scope and duration of the outbreak,
government actions and restrictive measures implemented in
response, material delays, supply chain disruptions and other
impacts to the business, or on the Company's ability to execute
business continuity plans as a result of the COVID-19 pandemic,
economic factors, such as interest rate and currency exchange rate
fluctuations; competition, including technological advances, new
products attained by competitors; challenges inherent in new
product development; the ability of the Company to successfully
execute strategic plans; the impact of business combinations and
divestitures; manufacturing difficulties or delays, internally or
within the supply chain; significant adverse litigation or
government action, including related to product liability claims;
changes to applicable laws and regulations, including tax laws;
changes in behavior and spending patterns of purchasers of products
and services; financial instability of international economies and
legal systems and sovereign risk. A further list and descriptions
of these risks, uncertainties and other factors can be found within
the Company's related filings with the Bolsa Mexicana de Valores.
Any forward-looking statement made in this release speaks only as
of the date of this release. The Company undertakes no obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
View original
content:https://www.prnewswire.com/news-releases/genomma-lab-pharma-manufacturing-facility-granted-pending-gmp-certification-for-the-mexican-market-302266133.html
SOURCE Genomma Lab Internacional, S.A.B. de C.V.